Telehealth ADHD Prescribing: What Psychiatrists Can Do in Texas

If you’re a psychiatrist considering telehealth ADHD care, you’re probably asking: Can I legally prescribe stimulants like Adderall through a video visit? What about my state’s rules? And will I actually get paid for it?

The short answer: Yes, psychiatrists can prescribe ADHD medications via telehealth in 2026 – but the rules depend on where you practice, and the regulatory landscape is shifting. This guide cuts through the noise to explain exactly what you can do, which states make it easy (or complicated), and how the economics actually work.

Federal Telehealth Prescribing: What’s Allowed Right Now

Under normal circumstances, the Ryan Haight Act (2008) requires at least one in-person exam before prescribing Schedule II controlled substances like Adderall or Vyvanse. That would make virtual-first ADHD care nearly impossible.

But we’re not operating under normal circumstances.

The COVID-19 public health emergency triggered a federal waiver allowing prescribers to initiate stimulant prescriptions entirely via telehealth – no initial in-person visit required. That flexibility has been extended multiple times, most recently through December 31, 2025 by the DEA and HHS.

What this means for you today:

• You can conduct a comprehensive ADHD evaluation via video
• You can prescribe Adderall, Ritalin, Vyvanse, and other Schedule II stimulants to new patients you’ve never met in person
• You can manage ongoing medication follow-ups entirely through telehealth
• All of this applies across state lines if you hold the appropriate state license where the patient is located

The catch: This is still a temporary extension. Unless Congress passes permanent legislation or the DEA creates new rules (like a proposed ‘telemedicine special registration’), we could revert to the Ryan Haight Act’s in-person requirement sometime in 2026. The telehealth community is watching closely, and multiple bills have been introduced to make these flexibilities permanent.

For now, proceed with confidence – but have a contingency plan. Some platforms are already establishing partnerships with local clinics for in-person exams if needed, or pivoting to hybrid models where the initial visit happens in-person and follow-ups are virtual.

Free consultations available with select providers only.

Grow your practice on Klarity

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Start seeing patients

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

State-by-State Breakdown: Where ADHD Telehealth Works (and Doesn’t)

Federal flexibility is one thing. State medical boards are another. Here’s what you need to know about the six states with the highest demand for ADHD prescribers:

California

Bottom line: Telehealth-friendly for ADHD prescribing; increasingly supportive of NP independence.

• Psychiatrists (MD/DO): Full authority to prescribe stimulants via telehealth. No state restrictions beyond federal law.
• PMHNPs: Must complete 3 years/4,600 hours under physician supervision before achieving independent ‘104 NP’ status. Once independent, can prescribe all ADHD meds. Must complete a specialized pharmacology course for Schedule II authority.
• Telehealth specifics: No in-person mandate. E-prescribing required for all controlled substances (since 2022). Strong telehealth parity – private insurers pay equal rates for video visits.
• Market reality: High demand in Bay Area and SoCal, but also significant rural gaps (Central Valley, Inland Empire). About 7,800 psychiatrists statewide but still a 1:5,636 ratio. Competitive in urban areas but underserved outside metro regions.

Practical tip: If you’re a new PMHNP in CA, plan for that supervised period. If you’re an experienced NP from another state, California’s pathway to independence makes it worth obtaining a CA license once you hit the hours threshold.

Texas

Bottom line: Psychiatrists are essential; NPs face severe restrictions.

• Psychiatrists (MD/DO): Can prescribe ADHD medications via telehealth without additional state barriers (video required, not audio-only).
• PMHNPs: Cannot prescribe Schedule II stimulants in outpatient settings – period. Texas law limits NP Schedule II prescribing to inpatient hospitals, ERs, or hospice only. This makes PMHNPs essentially unable to manage first-line ADHD treatment independently in routine practice.
• Telehealth specifics: Texas allows controlled substance prescribing for psychiatric disorders via video (not for chronic pain management, but ADHD doesn’t fall under that restriction). No state-imposed in-person requirement for mental health telehealth.
• Market reality: Severe shortage – 1 psychiatrist per 9,327 residents (43rd worst in the US). Over 185 of 254 counties are shortage areas. High demand, but also heightened scrutiny of telehealth prescribing after some high-profile abuse cases.

Practical tip: If you’re a psychiatrist, Texas is a goldmine – you’re one of the only providers legally able to prescribe Adderall there. If you’re a PMHNP, you’ll need a collaborating psychiatrist to handle stimulant prescriptions, or focus on non-stimulant ADHD medications (atomoxetine, bupropion, guanfacine).

Florida

Bottom line: Telehealth explicitly allowed for psychiatric prescribing; NPs need physician oversight but can prescribe beyond the typical 7-day limit.

• Psychiatrists (MD/DO): Full authority. Florida statute explicitly permits telehealth prescribing of Schedule II medications for psychiatric disorders (including ADHD).
• PMHNPs: Require a written supervisory protocol with a psychiatrist. General Florida law limits NPs to 7-day supplies of Schedule II drugs, but there’s a critical exception for ‘psychiatric nurses’ working under a psychiatrist’s protocol – they can prescribe standard 30-day supplies of psychotropic controlled substances.
• Telehealth specifics: Florida’s telehealth law is one of the most progressive – explicitly carves out psychiatric disorders as an exception to controlled substance restrictions. Mandatory PDMP checks before prescribing.
• Market reality: 1 psychiatrist per 8,577 residents (42nd worst nationally). High growth state with significant demand, especially in North Florida and rural areas. Miami/South Florida more saturated but still need for child/adolescent ADHD specialists.

Practical tip: If you’re a PMHNP in Florida, make sure your collaborative agreement explicitly addresses the psychiatric nurse exception so you can prescribe 30-day supplies. Document the psychiatrist relationship clearly to avoid issues with pharmacies or insurance.

New York

Bottom line: One of the best states for experienced NPs; strong telehealth infrastructure.

• Psychiatrists (MD/DO): Full independent authority, no restrictions.
• PMHNPs: Must complete 3,600 supervised hours (roughly 2 years), after which they can practice completely independently including prescribing all Schedule II-V medications without physician oversight. During the supervised period, collaboration required but no prescribing restrictions.
• Telehealth specifics: Strong parity laws. Mandatory e-prescribing and mandatory PDMP check for every controlled substance prescription (stricter than most states). No state barrier to telehealth CS prescribing.
• Market reality: Best psychiatrist supply in the nation (1:2,912 in NYC area), but upstate rural regions severely underserved. High insurance penetration, strong Medicaid telehealth coverage.

Practical tip: New York is ideal for experienced PMHNPs who want autonomy. If you’ve practiced elsewhere for 2+ years, getting NY licensed and hitting that 3,600-hour mark opens up full independence. The PDMP check requirement is non-negotiable – build it into your workflow or risk compliance issues.

Pennsylvania

Bottom line: Moderate access; NP prescribing hampered by restrictive quantity limits.

• Psychiatrists (MD/DO): Full authority with no state-specific telehealth barriers.
• PMHNPs: Require collaborative agreement. Major restriction: Can only prescribe 72-hour supply of Schedule II for initial prescriptions, and maximum 30-day supply for ongoing care (patient must be re-evaluated by supervising physician before extending beyond 30 days). No independent practice.
• Telehealth specifics: No explicit state prohibition on controlled substance prescribing via telehealth; follows federal guidance. Telehealth parity established through regulatory directive.
• Market reality: 1 psychiatrist per 4,586 residents (slightly better than average). Philadelphia and Pittsburgh well-served; central/rural PA underserved. One physician can collaborate with up to 4 NPs.

Practical tip: That 72-hour initial limit is a workflow killer for NPs. Common workaround: have the collaborating psychiatrist write the first prescription, then NP takes over for monthly refills. If you’re a psychiatrist in PA, you may be asked to co-sign or directly handle initial ADHD prescriptions for NP colleagues.

Illinois

Bottom line: Transitioning to NP independence; strong telehealth support.

• Psychiatrists (MD/DO): Full independent authority.
• PMHNPs: Can achieve Full Practice Authority after 4,000 clinical hours + 250 hours additional training. Once FPA granted, can prescribe all medications including Schedule IIs independently (though technically there’s a physician consultation requirement for Schedule II narcotics – pain meds – this doesn’t apply to ADHD stimulants). Before FPA, collaborative agreement required.
• Telehealth specifics: Strong telehealth parity law (2021). E-prescribing mandate for controlled substances (since 2023). Patient consent for telehealth must be documented.
• Market reality: 1 psychiatrist per 5,989 residents. Chicago saturated, downstate Illinois significantly underserved. Growing number of independent PMHNPs due to FPA pathway.

Practical tip: Illinois offers a clear path to NP independence – if you’ve got the hours, apply for FPA status. The state’s robust Medicaid telehealth coverage means you can serve a broader population than in some other states.

The Real Economics: What ADHD Telehealth Actually Pays

Let’s talk numbers, because ‘Can I do this?’ is only half the question. The other half is ‘Will it be worth my time?’

Insurance reimbursement for telehealth medication management is essentially at parity with in-person visits across all priority states. Here’s what you can expect:

Medicare Rates (2024-2025 fee schedule):

• Initial psychiatric evaluation (CPT 90792): ~$188-202
• 15-minute med check (CPT 99213): ~$89-95
• 25-minute med check (CPT 99214): ~$125-136

Commercial Insurance:

Generally pays equal to or 10-30% higher than Medicare. Typical range:

• Initial eval: $150-300
• Follow-up (99213): $90-120
• Follow-up (99214): $130-160

Medicaid:

Significantly lower but improving. Typical rates:

• 99213: $40-65
• 99214: $64-85

Why telehealth economics actually work better than traditional practice:

1. No office overhead – You’re not paying rent, utilities, or front-desk staff for an office you’re not using.

2. Higher scheduling efficiency – No-show rates tend to be lower (patients at home, no commute excuses). You can often see more patients per hour via video than in-person due to reduced transition time.

3. Geographic flexibility – You can serve patients across an entire state (or multiple states if multi-licensed), not just a 20-mile radius.

4. Lower patient acquisition cost – Here’s where platforms like Klarity make sense.

The Patient Acquisition Problem (and Why Platforms Solve It)

Here’s what most providers don’t calculate: the true cost of getting a qualified patient through your door.

If you’re building an independent telehealth practice, your real costs for acquiring an ADHD patient typically run $200-500+ per booked patient when you factor in:

• SEO investment (6-12 months before meaningful results, requires ongoing content and technical optimization)
• Google Ads for competitive mental health keywords ($15-40 per click; conversion rates of 2-5% mean you’re paying $200-400+ per booked patient)
• Psychology Today and directory listings (monthly fees + you’re competing with hundreds of providers on the same page)
• Staff time to handle, qualify, and schedule leads
• No-show rates from cold leads who found you online
• Failed marketing campaigns before you find what works

The Klarity model removes all that uncertainty:

Instead of spending $3,000-5,000/month on marketing with no guarantee of results, you pay a standard listing fee per patient who actually books with you. That’s it.

• No upfront marketing spend or monthly subscriptions
• Pre-qualified patients already matched to your specialty and availability
• No wasted budget on clicks that don’t convert
• Built-in telehealth infrastructure (no separate platform costs)
• Both insurance and cash-pay patient flow
• You control your schedule – only pay when you see patients

It’s the difference between gambling thousands on marketing channels versus guaranteed ROI. For most providers, especially those starting out or scaling, having a platform handle patient acquisition removes the single biggest barrier to building a sustainable practice.

Clinical Workflow: What ADHD Telehealth Actually Looks Like

The standard of care doesn’t change just because you’re on video. Here’s what a compliant ADHD telehealth workflow involves:

Initial Evaluation (45-60 minutes):

• Comprehensive psychiatric interview (DSM-5 criteria for ADHD)
• Collateral information when possible (rating scales, school/work records)
• Rule out other conditions (anxiety, bipolar, substance use that might mimic ADHD)
• Review of systems, medication history, family history
• Obtain baseline vitals (many providers ask patients to check BP at a pharmacy or use home monitor)
• Discuss treatment options, risks/benefits of stimulants
• Document everything thoroughly

E-Prescribing:

• Use DEA-compliant EPCS (Electronic Prescribing for Controlled Substances) system with two-factor authentication
• Check state PDMP before prescribing (mandatory in NY, FL, required for opioids/benzos in TX/PA, best practice everywhere)
• Start with lowest effective dose; stimulants are typically non-refillable so each month requires a new prescription

Follow-up Visits (10-15 minutes monthly):

• Symptom monitoring (using standardized scales like ADHD-RS or clinical interview)
• Side effect check (appetite, sleep, cardiovascular symptoms, mood changes)
• Adherence assessment
• Dose adjustment if needed
• Periodic coordination with primary care (especially for vitals monitoring in patients with cardiac history)

Safeguards to Implement:

Given increased scrutiny after some telehealth platforms overprescribed stimulants, legitimate providers emphasize:

• Thorough initial evaluations (not 10-minute questionnaires)
• Regular follow-ups (not ‘refill mills’)
• Urine drug screening when clinically indicated
• Patient agreements outlining expectations and responsibilities
• Careful documentation of medical necessity

The goal: Demonstrate that your telehealth ADHD care meets or exceeds the in-person standard. Florida law explicitly requires this, and medical boards everywhere expect it.

Common Provider Questions

Q: What happens if federal telehealth flexibilities expire in 2026?

A: Some platforms are establishing partnerships with local clinics for hybrid care (initial visit in-person, follow-ups virtual). Others are advocating for state-level changes. The most likely scenario is Congress extends or makes permanent the current flexibility given bipartisan support for telehealth access – but have a backup plan.

Q: Can I prescribe across state lines?

A: You need a medical license in every state where your patients are located. Some states participate in interstate compacts (like the Interstate Medical Licensure Compact for physicians) that streamline multi-state licensing. Most telehealth platforms handle credentialing across states.

Q: What about the ADHD medication shortage?

A: Adderall and some other stimulants have faced intermittent shortages since late 2022. The DEA increased production quotas in 2024, improving availability, but supply issues persist. Be prepared to prescribe alternative medications (Vyvanse, Concerta, or non-stimulants like atomoxetine) and coordinate with multiple pharmacies if needed.

Q: How do I avoid regulatory scrutiny?

A: Follow the standard of care rigorously. Document comprehensive evaluations. Schedule appropriate follow-ups. Use the PDMP consistently. Avoid prescribing to anyone who seems to be seeking drugs rather than treatment. The DEA and state boards are cracking down on ‘pill mills’ – make sure your practice doesn’t look like one.

Q: Do patients prefer telehealth for ADHD care?

A: Overwhelmingly yes, particularly adults. The convenience factor (no time off work, no commute, privacy of home) plus the severe shortage of local providers means telehealth is often the only realistic option. Pediatric ADHD can be more complex (parents may prefer in-person for initial visits), but follow-ups work well via video for most families.

Why Join a Platform vs. Solo Telehealth Practice?

Solo practice advantages:

• Keep 100% of revenue
• Full control over schedule and rates
• Build your own brand

Solo practice challenges:

• Months of SEO and marketing before first patient
• Ongoing marketing costs ($3,000-5,000+/month to maintain patient flow)
• Technology infrastructure (EHR, telehealth platform, e-prescribing, HIPAA compliance)
• Credentialing with insurance panels (6-12 months)
• Billing and collections
• Managing no-shows and cancellations
• Risk of slow patient growth

Platform advantages:

• Immediate patient flow (start seeing patients within days of credentialing)
• Zero marketing costs or risk
• Telehealth infrastructure provided
• Billing handled
• Predictable economics (know your per-visit fee)
• Multi-state credentialing support
• Flexibility to scale up or down

The reality: Most providers who try solo telehealth either fail to get traction (can’t acquire enough patients cost-effectively) or burn out managing all the non-clinical work. Platforms remove the entrepreneurial risk while letting you focus on what you actually went to medical school for.

The Opportunity in 2026

ADHD diagnosis and treatment exploded during the pandemic – stimulant prescriptions for adults aged 22-44 jumped significantly from 2020-2022. That demand hasn’t gone away. If anything, it’s intensified as:

• Stigma around ADHD treatment decreases
• More adults realize they have undiagnosed ADHD
• Traditional psychiatric practices remain inaccessible (months-long waitlists, no providers accepting new patients)
• Medication shortages highlight how many people depend on treatment

The supply side hasn’t caught up. In Texas, Florida, Pennsylvania, and rural parts of every state, there simply aren’t enough psychiatrists. Even in ‘well-supplied’ states like New York and California, appointment wait times for ADHD evaluation can be 3-6 months.

For psychiatrists, this is one of the best opportunities in telehealth. You have unrestricted prescribing authority in every state, you’re in desperately short supply, and you can command strong reimbursement rates.

For experienced PMHNPs, states with full practice authority (NY, IL, and soon CA) offer the chance to build independent practices serving ADHD patients who have nowhere else to turn.

The regulatory environment is mostly favorable (at least through 2025), reimbursement is solid, and patient demand is off the charts.

Next Steps: Getting Started with ADHD Telehealth

If you’re ready to explore ADHD medication management via telehealth:

1. Verify your state licenses – Make sure you’re licensed in states where you want to practice. If you’re considering multi-state practice, look into the Interstate Medical Licensure Compact.

2. Understand your state’s specific rules – Review the requirements in your state(s) for PDMP checks, e-prescribing, and any NP collaboration needs.

3. Get DEA-compliant e-prescribing set up – If you don’t already have EPCS capability, you’ll need it.

4. Decide on your practice model – Solo practice, join an existing group, or work with a platform that handles patient acquisition and infrastructure.

5. Consider Klarity Health – If the idea of guaranteed patient flow, zero marketing costs, and a pay-per-appointment model appeals to you, joining Klarity’s network means you can start seeing ADHD patients within weeks instead of months. You set your schedule, we handle the rest.

The ADHD telehealth opportunity isn’t going away. The question is whether you’ll spend years and thousands of dollars building independent patient flow, or whether you’ll partner with a platform that removes the risk and lets you focus on clinical care from day one.

Sources and Verification

The regulatory and clinical information in this guide was compiled from official state statutes, federal agency guidance, peer-reviewed sources, and recent healthcare policy reporting. All sources were accessed and verified in February 2026:

Federal Regulations & Policy

• DEA/HHS joint announcement extending COVID-era telehealth prescribing flexibility through December 31, 2025 (Axios, November 18, 2024)
• Ryan Haight Act background and current enforcement status (Axios, September 18, 2024)
• Federal telemedicine prescribing policy landscape (RxAgent, December 28, 2025)

State Laws & Regulations

• Florida: Florida Statutes §456.47 (telehealth controlled substance exceptions for psychiatric disorders), §464.012 (APRN prescribing authority and psychiatric nurse exception to 7-day limit) – Florida Legislature Official Site, 2023-2024 editions
• Texas: SB 2527 analysis on telehealth prescribing concerns (Texas Legislature, 88th Session, April 2023); Texas telemedicine standards (CCHP, January 19, 2026)
• California: AB 890 implementation for NP independence pathway (RxAgent, 2025); CA NP Schedule II pharmacology requirements
• New York: NP Modernization Act details (RxAgent, 2025); mandatory PDMP requirements
• Pennsylvania: PA CRNP prescribing limitations for Schedule II (Pennsylvania Code §21.284; RxAgent summary, 2025)
• Illinois: Illinois Nurse Practice Act (225 ILCS 65) on Full Practice Authority requirements; collaborative agreement rules

Market Data & Workforce Analysis

• State-by-state psychiatrist-to-population ratios (Healing Psychiatry Florida analysis, January 15, 2026, compiled from HRSA data)
• Psychiatrist shortage rankings and specific state ratios for TX, FL, NY, PA, IL, CA
• Texas mental health workforce shortage details (Texas Tribune, February 21, 2023)

Reimbursement Information

• Medicare psychiatry reimbursement rates 2024-2025 (Therathink insurance reimbursement guide, 2026 edition)
• CPT code payment details for 90792, 99213, 99214 across Medicare, Medicaid, commercial insurance
• Telehealth parity status across states (BehaveHealth analysis, 2024; CCHP state law database, 2026)

Clinical & Trend Data

• ADHD prescription surge during pandemic (Associated Press/JAMA Psychiatry, January 10, 2024)
• Stimulant medication shortages and DEA production quota increases (Axios, September 5, 2024; multiple Axios Vitals newsletters 2023-2024)
• Telehealth ADHD prescribing concerns and regulatory scrutiny (Texas SB 2527 analysis, 2023)

Verification Standards: All state-specific prescribing requirements were cross-referenced with official state statutes or regulatory guidance where available. Recent legislative changes (2023-2025) were verified through official legislative analysis documents. Market data reflects 2025-2026 figures. Reimbursement rates are based on published Medicare fee schedules and industry analysis for 2024-2025. Federal policy status reflects November 2024 DEA extension announcement, the most recent official guidance available.

Reliability Assessment: Official government sources (state statutes, federal agency announcements) rated as high reliability. Industry analyses and healthcare journalism (Axios, AP, Therathink, RxAgent) rated as medium-high reliability when citing official data sources. All regulatory claims can be verified through cited official sources. Economic claims (patient acquisition costs, marketing expenses) reflect general industry consensus and provider experience rather than specific published studies, as this data varies significantly by market and provider type.

Source:

• https://www.axios.com/2024/09/18/telehealth-services-controlled-substances-congress#:~:text=Why%20it%20matters%3A%20Pandemic,end%20of%20this%20year%20after
• https://www.axios.com/2024/11/18/covid-telehealth-prescribing-extended-adderall#:~:text=The%20Drug%20Enforcement%20Administration%20and,the%20third%20temporary%20extension%20of
• https://www.flsenate.gov/Laws/Statutes/2023/456.47#:~:text=,is%20prescribed%20for%20the%20following
• https://www.flsenate.gov/Laws/Statutes/2023/456.47#:~:text=1,disorder
• https://rxagent.co/blog/np-prescribing-authority#:~:text=OK%20%20,day%20%28ongoing%29%20%5B3
• https://rxagent.co/blog/np-prescribing-authority#:~:text=TN%20%20,NP%3A%20Independent%20%5B3
• https://rxagent.co/blog/np-prescribing-authority#:~:text=match%20at%20L210%20NY%20,terminal%20illness%2C%20MD%20initiation
• https://rxagent.co/blog/np-prescribing-authority#:~:text=ID%20%20,3
• https://rxagent.co/blog/np-prescribing-authority#:~:text=FL%20%20,NP%3A%20Independent%20%5B3
• https://www.leg.state.fl.us/STATUTeS/index.cfm?Appmode=DisplayStatute&Search_String=&URL=0400-0499%2F0464%2FSections%2F0464.012.html#:~:text=also%20limit%20the%20prescribing%20of,shall%20adopt%20by%20rule%20the